175 related articles for article (PubMed ID: 18231901)
1. Go with the flow for monitoring response in myeloma with minimal residual disease.
Mason KD; Juneja S
Leuk Lymphoma; 2008 Feb; 49(2):177-8. PubMed ID: 18231901
[No Abstract] [Full Text] [Related]
2. Introduction to multiple myeloma special issue: The flow cytometric detection of minimal residual disease.
Preffer FI; Yuan CM; Lin P; Stetler-Stevenson M; Marti GE
Cytometry B Clin Cytom; 2016 Jan; 90(1):9-10. PubMed ID: 26780351
[No Abstract] [Full Text] [Related]
3. [Detection of minimal residual disease in leukemia using flow cytometry].
Muroi K
Rinsho Ketsueki; 2008 Jun; 49(6):397-407. PubMed ID: 18646607
[No Abstract] [Full Text] [Related]
4. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.
Flores-Montero J; de Tute R; Paiva B; Perez JJ; Böttcher S; Wind H; Sanoja L; Puig N; Lecrevisse Q; Vidriales MB; van Dongen JJ; Orfao A
Cytometry B Clin Cytom; 2016 Jan; 90(1):61-72. PubMed ID: 26100534
[TBL] [Abstract][Full Text] [Related]
5. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting.
Arroz M; Came N; Lin P; Chen W; Yuan C; Lagoo A; Monreal M; de Tute R; Vergilio JA; Rawstron AC; Paiva B
Cytometry B Clin Cytom; 2016 Jan; 90(1):31-9. PubMed ID: 25619868
[TBL] [Abstract][Full Text] [Related]
6. Flow cytometry quality requirements for monitoring of minimal disease in plasma cell myeloma.
Oldaker TA; Wallace PK; Barnett D
Cytometry B Clin Cytom; 2016 Jan; 90(1):40-6. PubMed ID: 26201282
[TBL] [Abstract][Full Text] [Related]
7. Flow Cytometric MRD Detection in Selected Mature B-Cell Malignancies.
Böttcher S
Methods Mol Biol; 2019; 1956():157-197. PubMed ID: 30779035
[TBL] [Abstract][Full Text] [Related]
8. Role of Flow Cytometry in the Diagnosis and Prognosis of Plasma Cell Myeloma.
Olteanu H
Surg Pathol Clin; 2016 Mar; 9(1):101-16. PubMed ID: 26940271
[TBL] [Abstract][Full Text] [Related]
9. Regulatory perspective on minimal residual disease flow cytometry testing in multiple myeloma.
Gormley NJ; Turley DM; Dickey JS; Farrell AT; Reaman GH; Stafford E; Carrington L; Marti GE
Cytometry B Clin Cytom; 2016 Jan; 90(1):73-80. PubMed ID: 26108351
[TBL] [Abstract][Full Text] [Related]
10. A single-tube six-colour flow cytometry screening assay for the detection of minimal residual disease in myeloma.
de Tute RM; Jack AS; Child JA; Morgan GJ; Owen RG; Rawstron AC
Leukemia; 2007 Sep; 21(9):2046-9. PubMed ID: 17657223
[No Abstract] [Full Text] [Related]
11. Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition.
Stetler-Stevenson M; Paiva B; Stoolman L; Lin P; Jorgensen JL; Orfao A; Van Dongen J; Rawstron AC
Cytometry B Clin Cytom; 2016 Jan; 90(1):26-30. PubMed ID: 25907102
[TBL] [Abstract][Full Text] [Related]
12. Detection of minimal residual disease.
Deptala A; Mayer SP
Methods Cell Biol; 2001; 64():385-420. PubMed ID: 11070849
[No Abstract] [Full Text] [Related]
13. Minimal residual disease monitoring in multiple myeloma.
Davies FE; Rawstron AC; Owen RG; Morgan GJ
Best Pract Res Clin Haematol; 2002 Mar; 15(1):197-222. PubMed ID: 11987924
[TBL] [Abstract][Full Text] [Related]
14. An analysis of the false negative rate of minimal residual disease measurement by multiparameter flow cytometry in multiple myeloma.
Austin M; O'Connor S; Morilla R; Pawlyn C; Kaiser MF; Boyd KD
Int J Lab Hematol; 2020 Apr; 42(2):e65-e67. PubMed ID: 31539199
[No Abstract] [Full Text] [Related]
15. Minimal residual disease monitoring in multiple myeloma: flow cytometry is the method of choice.
Owen RG; Rawstron AC
Br J Haematol; 2005 Mar; 128(5):732-3; author reply 733-4. PubMed ID: 15725097
[No Abstract] [Full Text] [Related]
16. Measurable disease evaluation in patients with myeloma.
Roshal M
Best Pract Res Clin Haematol; 2020 Mar; 33(1):101154. PubMed ID: 32139019
[TBL] [Abstract][Full Text] [Related]
17. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders.
Rawstron AC; Orfao A; Beksac M; Bezdickova L; Brooimans RA; Bumbea H; Dalva K; Fuhler G; Gratama J; Hose D; Kovarova L; Lioznov M; Mateo G; Morilla R; Mylin AK; Omedé P; Pellat-Deceunynck C; Perez Andres M; Petrucci M; Ruggeri M; Rymkiewicz G; Schmitz A; Schreder M; Seynaeve C; Spacek M; de Tute RM; Van Valckenborgh E; Weston-Bell N; Owen RG; San Miguel JF; Sonneveld P; Johnsen HE;
Haematologica; 2008 Mar; 93(3):431-8. PubMed ID: 18268286
[TBL] [Abstract][Full Text] [Related]
18. Comparison of minimal residual disease detection in multiple myeloma between the DuraClone and EuroFlow methods.
Yoroidaka T; Narita K; Takamatsu H; Fujisawa M; Nakao S; Matsue K
Sci Rep; 2021 May; 11(1):11218. PubMed ID: 34045494
[TBL] [Abstract][Full Text] [Related]
19. Minimal Residual Disease Detection by Flow Cytometry in Multiple Myeloma: Why and How?
Roshal M
Semin Hematol; 2018 Jan; 55(1):4-12. PubMed ID: 29759152
[TBL] [Abstract][Full Text] [Related]
20. Minimal residual disease detection of myeloma using sequencing of immunoglobulin heavy chain gene VDJ regions.
Ho C; Arcila ME
Semin Hematol; 2018 Jan; 55(1):13-18. PubMed ID: 29759147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
